About us

Applying proprietary understanding to guide a precision medicine approach

We’re in business to deliver novel therapeutic opportunities to patients with serious digestive system disorders where there exists a high unmet clinical need

Our unique insights Better understanding our target

At ThirtyFiveBio, we have unique insights into the disease-causing nature of GPR35, aiding our understanding in the search for new therapies

Genetically validated
ID of an endogenous activation mechanism
Insight into signalling pathways
Precision association with disease subsets
Druggable target
Potential first-in-class antagonists

Our expertise GPR35 antagonism specialists

Network of industry and academic GPR35 specialists
Multi-omics approach to target validation
World-leading GPR35 antagonist medicinal chemistry
Application of patient-derived organoid disease models